ARTICLE | Company News
Bayer, J&J deal
October 31, 2005 8:00 AM UTC
The companies partnered to co-develop and co-commercialize BAYG's BAY 59-7939 to prevent and treat thrombosis. The Factor Xa inhibitor is in Phase IIb trials to prevent venous thromboembolism after ...